KARYOPHARM THERAPEUTICS INC
KPTINASDAQ🏆 #4677 by market capEarnings Nov 2US Equity
$1.21▼ $0.31 (−25.62%)
Market closed · at closeTrack KPTI
Get earnings, price moves & breaking news on Telegram
24h▼ 25.6%
7d▼ 31.3%
14d▼ 29.5%
30d▼ 41.6%
ytd▼ 83.7%
1y▼ 81.6%
🏦Market Cap
$27M
Small Cap
📈Revenue Growth (YoY)
+0.6%
Slowing
📊Gross Margin
95.9%
High
💵FCF Margin
-44.6%
Thin
⚖️P/S Ratio
0.2x
Cheap
Otter Score
48
Weak
KARYOPHARM THERAPEUTICS INC
KPTIAnalyst Ratings
Price
$1.21
Total
20
Raised
3
Lowered
3
Avg PT
$9.50
H / L
$16 / $3
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
Piper Sandler | Reiterated | Overweight | 2026-07-31 | $16.00 | +1227.80% |
HC Wainwright & Co. | Downgraded | Buy → Neutral | 2026-07-31 | — | — |
Baird | Reiterated | Outperform | 2026-03-25 | — | — |
RBC Capital | Reiterated | Outperform | 2025-11-04 | $16.00 | +1227.80% |
Barclays | Reiterated | Overweight | 2025-05-13 | — | — |
Morgan Stanley | Reiterated | Equal Weight | 2023-08-07 | — | — |
Wedbush | Reiterated | Neutral | 2023-07-26 | — | — |
SVB Leerink | Reiterated | Market Perform | 2023-01-10 | — | — |
JP Morgan | Upgraded | Underweight → Neutral | 2022-02-09 | — | — |
H.C. Wainwright | Reiterated | Buy | 2020-01-14 | $3.00 | +149.00% |
Canaccord Genuity | Reiterated | Buy | 2019-11-05 | — | — |
B of A Securities | Downgraded | Neutral → Underperform | 2019-02-27 | — | — |
Bank of America | Downgraded | Neutral → Underperform | 2019-02-27 | — | — |
Jefferies | Upgraded | Hold → Buy | 2016-08-30 | — | — |
Raymond James | Reiterated | Outperform | 2016-05-27 | — | — |
JMP Securities | Reiterated | Market Outperform | 2016-03-09 | — | — |
Leerink Swann | Reiterated | Outperform | 2015-11-10 | — | — |
Oppenheimer | Upgraded | Market Perform → Outperform | 2014-11-10 | — | — |
Barrington Research | Reiterated | Buy | 2014-11-05 | — | — |
MLV & Co. | Reiterated | Buy | 2014-11-05 | — | — |
Institution
Piper Sandler
Reiterated · Overweight · 2026-07-31
$16.00
+1227.80%
HC Wainwright & Co.
Downgraded · Buy → Neutral · 2026-07-31
—
—
Baird
Reiterated · Outperform · 2026-03-25
—
—
RBC Capital
Reiterated · Outperform · 2025-11-04
$16.00
+1227.80%
Barclays
Reiterated · Overweight · 2025-05-13
—
—
Morgan Stanley
Reiterated · Equal Weight · 2023-08-07
—
—
Wedbush
Reiterated · Neutral · 2023-07-26
—
—
SVB Leerink
Reiterated · Market Perform · 2023-01-10
—
—
JP Morgan
Upgraded · Underweight → Neutral · 2022-02-09
—
—
H.C. Wainwright
Reiterated · Buy · 2020-01-14
$3.00
+149.00%
Canaccord Genuity
Reiterated · Buy · 2019-11-05
—
—
B of A Securities
Downgraded · Neutral → Underperform · 2019-02-27
—
—
Bank of America
Downgraded · Neutral → Underperform · 2019-02-27
—
—
Jefferies
Upgraded · Hold → Buy · 2016-08-30
—
—
Raymond James
Reiterated · Outperform · 2016-05-27
—
—
JMP Securities
Reiterated · Market Outperform · 2016-03-09
—
—
Leerink Swann
Reiterated · Outperform · 2015-11-10
—
—
Oppenheimer
Upgraded · Market Perform → Outperform · 2014-11-10
—
—
Barrington Research
Reiterated · Buy · 2014-11-05
—
—
MLV & Co.
Reiterated · Buy · 2014-11-05
—
—
One row per institution · price target from the firm's latest published target
StockOtter · stockotter.space